CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 77.3% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Bristol Myers BMY

Verkoop
 Koop

BristolMyers live grafieken

5m 15m 30m 1h 4h 1d 1w

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

BristolMyers news

Magnificent 7 earnings, US and Japan inflation due next week
Neil Wilson 2024 Jul 18, 16:00

Week ahead: Magnificent 7 earnings, 2 key inflation reports

Forex Indices
Wall Street earnings
Neil Wilson 2023 Oct 20, 10:00

Week ahead: Earnings bonanza, ECB decision & US inflation

Forex Indices
Megacap-tech-stocks.jpg
Neil Wilson 2023 Apr 21, 05:00

Week ahead: Megacap tech and 1-in-3 Dow components set to report

2022 Jul 24, 05:42

Week ahead: Fed to hike 100bps into a recession?

Laatste marktnieuws

Toon meer
Frances Wang 2025 Apr 27, 16:00

ETFs That Outperform the S&P 500: ARKK, VGT, IWF, XBI

ETFs
Frances Wang 2025 Apr 27, 16:00

Forex Market Today: Analyzing Seasonal Patterns in Forex Market Trends

Forex
Frances Wang 2025 Apr 27, 16:00

Dow Jones today: Major Indexes Rise as Trump Signals Softer Trade Stance

Stocks
Tommy Yap 2025 Apr 27, 16:00

Morning Note: Gold Dips on Dollar Strength, ECB Eyes Rate Cut, Japan Denies FX Pressure

Morning Note Commodities Forex
Tommy Yap 2025 Apr 26, 21:00

Week Ahead: Canada Election and U.S. NFP in Focus

Forex Indices
Frances Wang 2025 Apr 24, 16:00

How will tariffs affect forex: EUR/USD pair weakens amid trade uncertainty

Forex
Frances Wang 2025 Apr 24, 16:00

Exchange Traded Funds News: Tech-Focused ETFs Gain Traction Amid AI Boom

ETFs
Tommy Yap 2025 Apr 24, 16:00

Morning Note: US-China Trade Deadlock; Nvidia's AI Leap; Canada Votes

Morning Note CAD Forex

Info

Spread

0.29

Spread (%)

0.6038 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt openen

Maandag

13:31 - 19:59

Dinsdag

13:31-19:59

Woensdag

13:31-19:59

Donderdag

13:31-19:59

Vrijdag

13:31-19:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

99087859712

Uitstaande aandelen

2035079936

Datum winstcijfer (volgende)

2001-08-07

Div. rend.

2025-05-01

Ex-dividenddatum

2025-04-04

Jaarlijks verwachte dividendpercentage

2.48

Jaarlijks verwachte dividendrendement

0.0518

Winst per aandeel

2.68

Meer informatie over dit instrument

Bristol Myers Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering

Handel nu

Handel nu

Handel nu

Handel nu
Gerelateerde instrumenten

latest_education_articles

Toon meer
Trustpilot